Wockhardt Limited (WOCKPHARMA) Q2 FY27 Financial Results: PAT ₹107 Cr & Revenue ₹929 Cr

10 August 2026 · NSE 🔴 High Importance ✨ Positive

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

Metric	Value
Revenue	₹929 Cr
Net Profit (PAT)	₹107 Cr

📢 Key Event

Wockhardt reports Q1 FY27 results showing PAT of Rs.107 crores and 26% revenue growth

🔄 What Changed

PAT turned positive from Rs.108 crore loss, EBITDA grew 86% to Rs.188 crores, revenue grew 26% to Rs.929 crores

🔮 What's Next

Upcoming launch of Insulin analogs over next few years

💡 Investor Takeaway

The company is showing strong recovery with profitable growth and expanding international biotech operations.

Wockhardt reported a 26% YoY revenue increase to Rs.929 crores for Q1 FY27, driven by strong growth in emerging markets and biotech segments, while PAT reached Rs.107 crores after a turnaround from a Rs.108 crore loss in Q1 FY26. EBITDA grew 86% YoY to Rs.188 crores with margins expanding to 20.2%. PAT margin improved significantly to 11.5% from -14.6% in the prior year.

📄 View Original Announcement (PDF)

📊 Stock Analysis — WOCKPHARMA ✨ Ask AI About This

About Wockhardt Limited (WOCKPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹35,540.29 CrP/E: 86.8ROE: 8.3%ROCE: 9.6%

View full WOCKPHARMA stock details →

📡 Get AI alerts when WOCKPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track WOCKPHARMA — Free

💡 Ask AI about this filing

"What is the projected revenue contribution from insulin analogs launch?""How does EBITDA margin compare to peers in biotech sector?""What is the expected timeline for EMA approval of Zaynich?"

Ask AI Free →

📊 More WOCKPHARMA filings

Announcement — 25 September 2026Wockhardt Ltd announced the closure of its trading window effective October 1, 2026, following regul...
🟡 Board Meeting — 5 August 2026Wockhardt Limited announced an addendum to its notice for the 27th Annual General Meeting, revising ...
share transfer — 10 July 2026Wockhardt Limited received a SEBI-mandated share transfer agent certificate for the quarter ended Ju...
🟡 concall transcript — 30 June 2026Wockhardt's investor call on June 4, 2026, highlighted the US FDA approval of Zaynich, its first Ind...
Financial Results — 25 June 2026Wockhardt Limited announced that its trading window for equity shares will close on 1 July 2026 and ...

See all WOCKPHARMA filings →

🔥 Also filed on 10 August 2026

TIMKENTimken India LimitedFinancial Results DOMSDOMS Industries LimitedCorporate Action HGSHinduja Global Solutions LimitedFinancial Results SUNDRMFASTSundram Fasteners LimitedFinancial Results AMJLANDAmj Land Holdings LimitedAnnual Report KANSAINERKansai Nerolac Paints LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when WOCKPHARMA files new disclosures

Track WOCKPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.